Algorae Pharmaceuticals Limited (LVCLF) Stock

About Algorae Pharmaceuticals Limited

Algorae Pharmaceuticals Limited, established in 1987 and based in Melbourne, Australia, is a pharmaceutical development company. The firm primarily conducts its research and development in New Zealand, focusing on living cell technologies. Its product pipeline includes several key candidates: AI-116, a novel combination therapy featuring cannabidiol and an existing pharmaceutical ingredient, intended for the treatment of dementia, including Alzheimer's disease; NTCELL, an alginate-coated capsule developed to address Parkinson's disease; and AI-168, another combination drug that combines a cannabinoid with an off-patent pharmaceutical ingredient, aimed at treating cardiovascular conditions like hypertension. Furthermore, in partnership with the University of New South Wales, Algorae is developing AlgaraeOS, an artificial intelligence platform designed to predict biopharmaceutical drug targets, including both fixed-dose combinations and repurposed drugs, without being limited by specific medical indications. The company previously operated as Living Cell Technologies Limited, rebranding to Algorae Pharmaceuticals Limited in September 2023.

Algorae Pharmaceuticals Limited is headquartered in AU.

Algorae Pharmaceuticals Limited (LVCLF) stock trades at $0.01 with a market capitalization of $16.36M. The stock is valued at a price-to-earnings (P/E) ratio of 26.00, price-to-book of 11.61, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.00 and $0.01, and currently trades at its 52-week high.

On profitability, Algorae Pharmaceuticals Limited generates a return on equity (ROE) of -49.25%, return on capital employed of -113.95%, an operating margin of 0.00%, a net profit margin of 0.00%.

Official website: www.algoraepharma.com